We assessed the efficacy and tolerability of onabotulinumtoxinA 200 U vs placebo to treat lower urinary tract symptoms/benign prostatic hyperplasia inmen previously treated with oral benign prostatic hyperplasia medication in a24-week phase 2 , multicenter , double-blind , randomized , placebo controlled , parallel group trial .